Blurbs

B.Riley Financial Keeps Their Hold Rating on Madrigal Pharmaceuticals (MDGL)

B.Riley Financial analyst Mayank Mamtani maintained a Hold rating on Madrigal Pharmaceuticals (MDGLResearch Report) today and set a price target of $75.00. The company’s shares opened today at $74.13.

Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -29.6% and a 22.16% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Madrigal Pharmaceuticals with a $149.50 average price target.

See the top stocks recommended by analysts >>

MDGL market cap is currently $1.26B and has a P/E ratio of -4.90.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Read More on MDGL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed